Ticker

No recent analyst price targets found for ECOR.

Latest News for ECOR

New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation

ROCKAWAY, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced the publication of the peer-reviewed review article, "Two Paths to the Body's Superhighway—The Auricular Branch (taVNS) and the Cervical Bundle (tcVNS): A Narrative Review," in Frontiers in…

GlobeNewsWire • Jul 16, 2026
RBC reiterates 'outperform' on Ecora Royalties after Voisey's Bay site visit boosts confidence

RBC Capital Markets has reiterated its 'outperform' rating and 185p price target on Ecora Royalties PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF, FRA:HGR) after a site visit to the Voisey's Bay cobalt and copper mine in Newfoundland and Labrador left the bank with materially greater confidence in the asset's operational delivery and growth potential. The note, from analysts Ben Davis, Laura Chan and Marina Calero, describes…

Proactive Investors • Jun 15, 2026
Frontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery

ROCKAWAY, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the review article, "Without getting under your skin: non-invasive stimulation activates the vagus nerve," has been accepted for publication in Frontiers in Neuroscience.

GlobeNewsWire • Jun 9, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for ECOR.

No House trades found for ECOR.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top